Bio

Seb Orton is a partner in the corporate team, based in the London office, and has extensive experience advising both private and public companies and financial institutions. His work covers a range of corporate issues with a particular focus on IPOs, secondary fund-raisings, M&A, including public company takeovers, and assisting listed companies on corporate governance and their continuing obligations. He has wide cross-sector experience and has acted on a full range of issuer and investment bank-side transactions, from a FTSE250 Main Market IPO for a financial institution and a high profile IPO on AIM to a variety of smaller Main Market and AIM transactions in the retail and health and care sectors. The most recent of these have included the AIM IPO of Fadel Partners, Inc. (acting for finnCap as nominated adviser and broker), the Main Market IPO of Oxford Cannabinoid Technologies Holdings plc (acting for the issuer) and a subsequent follow-on offering, the AIM IPO of Parsley Box Group plc (acting for finnCap as nominated adviser and broker), two equity fundraisings for SkinBioTherapeutics plc (acting for the issuer) and convertible debt offerings for both SkinBioTherapeutics and Oxford Cannabinoid Technologies Holdings. He was seconded to Investec's Corporate Finance Group in 2004 and Citigroup's ECM legal team in 2011 and has strong links with a variety of investment banks across the UK. Chambers UK describes Seb as ‘a known figure in the market for AIM IPOs and secondary offerings’ and as a ‘highly experienced practitioner with a wealth of knowledge’. He is also recognised in The Legal 500 for small and mid-cap flotations. He joined Penningtons Manches Cooper in 2019 from the City office of a leading international firm. Prior to that, he was a partner in the London office of a US law firm. Seb is a member of Penningtons Manches Cooper’s North America Group and has extensive experience working with US and Canadian companies both listing in London and acquiring UK public companies. He is also a member of the National Institute for Health Research’s i4i Challenge Funding Committee.